4. Introduction:-
⢠Prostate cancer is the 2nd most common
diagnosed malignancy (Incidence)
⢠5th leading cause of cancer-related death
⢠Most prevalent cancer of men
⢠Newer biomarkers needed for early detection
and therapeutic targets for needed
5. Prostate-specific antigen (PSA)
⢠PSA is present in small quantities in the serum of
men with healthy prostates
⢠PSA is the most used test to detect carcinoma.
⢠limited specificity and an elevated rate of over
diagnosis
6. PSA elevated in
ďprostate cancer,
ďprostatitis,
ďirritation,
ďbenign prostatic hyperplasia (BPH),
ďrecent ejaculation and
ďDigital rectal examination(DRE)
7. PSA in Serum
Disruption of this epithelium due to disease
diffusion of the antigen
into blood
causes of elevated blood levels of PSA
o Obesity reduce serum PSA levels
8. Screening
⢠annual screening in men of age 50 and older
⢠Normally less than 4 ng/mL
⢠PSA levels between 4 and 10 ng/mL are suspicious
for malignancy
⢠>10ng/mL considered as high risk for malignancy
10. Histology
⢠PSA is produced in the epithelial cells of the
prostate
⢠can be demonstrated in biopsy samples by using
IHC
⢠PSA remains present in malignant prostate cells
⢠Prostate cancer cells generally have variable or
weak staining for PSA due to the disruption of their
normal functioning
11. ⢠individual prostate cancer cells produce less PSA
than healthy cells.
⢠increased number of cells
causes raised serum levels
⢠identify metastasis.
⢠some high-grade prostate
cancers may be entirely negative for PSA
Normal prostate tissue with PSA IHC
12. PSA kinetics:-
⢠PSA velocity
ârate of increase of PSA per year (ng/ml/year)
âvaluable in prostate cancer prognosis.
âincreased by more than 2.0 ng per milliliter
during the year -higher risk of metastasis
⢠PSA doubling time (PSA DT)
âidentify life threatening disease before start of
treatment (n=>10 yrs)
13. Free PSA
⢠not protein bound - 'free PSA'.
⢠In prostate cancer the ratio of free (unbound) PSA
to total PSA is decreased.
⢠The risk of cancer increases if the free to total ratio
is less than 25%
⢠Help to eliminate unnecessary biopsies when PSA
levels between 4 and 10 ng/mL.
14. Inactive PSA
⢠Proteolytically active PSA has been shown to have
an anti-angiogenic effect
⢠inactive subforms are associated with prostate
cancer
⢠identified by MAb 5-D3-D11
⢠inactive proenzyme forms of PSA is another
potential indicator of disease.
15. PSA Density (PSA-D)
⢠PSA density =
total PSA (ng/ml)
prostate volume (ml)
⢠In benign diseases less than 0.06 ng/ml2
⢠Increased value associated with the risk prostatic
carcinoma
⢠Omitting prostate biopsy with Gleason Score âĽ7
tumors with PSA-density
ââ¤0.07âng/ml2 may miss 6.9%
â0.10âng/ml2 may miss1.3%
16. ⢠PSA-density
âInformation about biopsy decisions,
âspare some men from unnecessary prostate
biopsy and
âdiagnosis of low-grade prostate cancer.
BUT
⢠its use for biopsy decisions is conflicting
⢠not commonly recommended in guidelines
*NordstrĂśm, T., Akre, O., Aly, M., GrĂśnberg, H., & Eklund, M. (2017, December 19).
Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer.
https://www.nature.com/articles/s41391-017-0024-7
17. Post-treatment monitoring
⢠PSA levels are monitored periodically (every 6â36
months) after treatment of high-risk disease
⢠less frequently in patients with lower-risk disease
⢠After successful therapy PSA becomes undetectable
within a few weeks.
⢠A subsequent rise above 0.2 ng/mL - recurrence
18. ⢠After successful radiation therapy little PSA may be
detected
⢠recurrent prostate cancer - "biochemical
recurrence"
21. aggressiveness determination by
ď PHI and
ď the four kallikrein panel
assessment of cancer prognosis
ďProlarisÂŽ
ďOncotype DXÂŽ
ďProstate-Specific Membrane Antigen (PSMA)
select the treatment by
ď androgen receptor splice variant-7 (AR-V7)
22. PCA3
⢠only expressed in human prostate tissue
⢠the gene is highly overexpressed in prostate cancer
⢠because of its restricted expression profile, the
PCA3 RNA is useful as a tumor marker
⢠PCA3 is also known to as DD3
23. Discovery:-
⢠PCA3 was discovered in 1999 by MJ Bussemakers et.
al.
⢠done by comparing the mRNA expression patterns
of normal v/s tumor tissue of the human prostate
⢠then cDNA library of mRNA extracted
24. ⢠six overlapping genomic phages that cover
the DD3 gene were isolated and characterized
⢠then structure of the DD3 transcription unit
identified
Genetic structure of PCA3 gene
25. Genetic structure:-
⢠DD3/PCA3 gene present in ch 9q21â22
⢠three reading frames
⢠DD3 cDNA has the high density of stop codons
⢠lack of an extensive open reading frame.
⢠the DD3gene consists of four exons
26. ⢠alternative polyadenylation occurs at three different
positions in exon 4 (4a, 4b, and 4c)
⢠exon 2 is only present in 5% of the cDNA clones
⢠often skipped by alternative splicing
Structure of the DD3 transcription unit
27. ⢠the DD3 gene is about 25 kb
⢠the first exon is relatively large (appr. 20 kb);
⢠whereas exon 2,3 and 4 are small
⢠several small open reading frames scattered
throughout the DD3 gene
⢠located in exons 3 and 4a
⢠So, the protein product is likely to be very small.
28. Relation of PCA3 with Prostate cancer:-
⢠10â100 fold overexpression in the tumor areas than
adjacent non-neoplastic prostate tissue
⢠Expression is observed in almost all stages of the
tumors
⢠Up-regulation of DD3 expression is an early event in
prostate cancer development
29. ⢠PCA3 expression is found in well-differentiated,
moderately differentiated and poorly differentiated
tumors
⢠Trend toward more expression in the poorly
differentiated tumors
30. Use as biomarker
⢠Urine-based PCA3 diagnostic tests is noninvasive
⢠Compared to serum PSA, urinary PCA3 has
âlower sensitivity but
âhigher specificity and
âbetter positive and negative predictive value.
⢠PCA3 is independent of prostate volume compared
with PSA
31. ⢠Suspected by DRE and PSA, approximately 60% of
cases 1st biopsy is normal
⢠On repeat testing, 20-40% have an abnormal biopsy
result
⢠PCA3 is useful to avoid these repeated biopsy
⢠Also found in metastatic lesions
32. PCA3 and prognosis:-
⢠PCA3 score and grading correlated statically with
prognosis
⢠PCA3 score lower than 51 and Gsââ¤â6 shows
comparatively good prognosis
⢠PCA3 score higher than 51 and a GsââĽâ7 â poor
prognosis
33. Commercial availability:-
⢠A commercial kit called the Progensa PCA3 test is
marketed by Gen-Probe
⢠the first portion of urine
after prostate message
⢠The PCA3 Test measures
both PCA3 and PSA mRNA in a urine sample
⢠The PSA mRNA measurement ensures that prostate
cells were collected in the sample
34. ⢠Using RT-PCR , PCA3 and PSA mRNA are amplified
from the sample
⢠The result is reported as a ratio of PCA3 mRNA to
PSA mRNA
⢠samples having cancer -higher PCA3/PSA ratios
⢠PSA mRNA measurements below a certain
detection amount produce an inconclusive test
35. ⢠PCA3 levels were significantly higher among men
who were subsequently diagnosed
⢠the PCA3 score was significantly higher with
Gleason âĽ7 tumors , clinical stage T2 disease
36. PSA glycoforms
⢠Based on different glycosylation patterns between
PCA patients and healthy subjects
⢠Significant increase of ι2,3-sialic acid in malignancy
than BPH
⢠Identifies aggressive PCA and correlates with
Gleason score
37. ⢠The cutoff value is 30%
⢠Helps in differentiates between high-risk PCa and
the groups of BPH, low- and intermediate-risk PCa
⢠PSA fucosylation also increases
⢠Decrease in core fucosylation of PSA in carcinoma
38. TMPRSS2:ERG fusion gene
⢠Transmembrane Protease; Serine 2
⢠Common in hematologic malignancies
⢠Can be detected in urine samples obtained after a
prostate massage
⢠RT-qPCR
⢠TMPRSS2:ERG score =
TMPRSS2:ERG mRNA
PSA mRNA
39. ⢠TMPRSS2:ERG score and PCA3 score combined
significantly increased the predictive value of
diagnosis
⢠TMPRSS2:ERG score associated with â
ďthe biopsy Gleason score and
ďtumor clinical stage.
⢠ExoDx Prostate IntelliScore measures
ď PCA3, SPDEF, and ERG
40. MicroRNAs
⢠miRNAs are involved in all steps of carcinoma
development,
ďcell proliferation,
ďdifferentiation, and
ďprogression.
⢠cancer stem cells proliferation and differentiation
ďmiR-34 family and
ďlet-7 family upregulated
⢠apoptosis
ďmiR-21 is upregulated to reduce apoptosis
41. Circulating tumor cells
⢠Tumor cells can acquire the ability to pass vessel
walls and enter into the bloodstream.
⢠Facilitate the establishment of metastatic focus
⢠High proportions are commonly found in advanced
metastatic stages,
⢠Very rare in early stages
42. ⢠CTCs present a heterogeneous phenotype, due to-
ďintratumor heterogeneity and
ďdifferences between primary tumor and
metastases
⢠Heterogeneity linked with therapy resistance
⢠Help to make therapeutic decisions
⢠No sufficient prognostic value in localized ca.
43. ⢠CellSearchŽ platform has approved for monitoring
of metastatic breast, colon, and Prostate cancer
⢠Based on immunomagnetic capture followed by a
combination of positive and negative
immunological selections.
⢠In advanced stages, Androgen Deprivation Therapy
(ADT) help to slow carcinoma progression by CTC
identification
44. Androgen receptor(AR)
⢠SPOP or FOXA1 mutations
⢠Transcription factors are the main driver of CRPC
development
⢠AR gene amplification and overexpression,
⢠AR mutations, and
⢠expression of constitutively active AR variants
(AR-Vs).
⢠OncotypeDX AR-V7 Nucleus Detect
45. Prostate Health Index (PHI)
⢠PHI combines total PSA, fPSA, and p2PSA
â˘
⢠Useful in men >50 years, PSA between 4 and 10
Îźg/L, and a nonsuspicious digital rectal examination
(DRE).
⢠PHI demonstrated a higher accuracy than total PSA
and %fPSA
đđđ =
đŠđđđđ
đđđđ
đą đđ¨đđđĽđđđ
46. ⢠Significantly higher in patients with a Gleason score
âĽ7 than score 6.
⢠Values for PHI high in patients with clinical stage
T2âT3 than stage T1c.
⢠PHI density has a higher discriminative ability to
detect clinically significant PCa than PHI
48. ⢠To reduce the over detection
⢠30% of biopsies could be avoided
⢠able to predict the long term development of
distant metastasis
49. Prognostic factors
⢠Gleason score - most valuable and conventional
predictor
⢠Gleason score âĽ7 require a radical treatment
⢠Gleason score 6 could probably have carcinoma
with low risk of progression
⢠Active surveillance is the best option for them.
50. Prolaris test
Oncotype DX test
⢠Recommends for very-low and low risk PCa in
patients
⢠Choice between active surveillance and definitive
therapy.
⢠Prolaris evaluate of 31 cell cycle progression genes
related to cancer proliferation
⢠Oncotype DX test evaluate 5 housekeeping genes
related to metastasis.
51. Prostate-Specific Membrane Antigen
⢠Transmembrane protein
⢠Expressed in all types of prostatic tissue
⢠Acts as a glutamate-preferring carboxypeptidase
⢠Upregulated in androgen deprivation
⢠Independent indicator of poor prognosis
⢠Possible target for chemotherapy
52. Recent Biomarkers
⢠Prostate Stem Cell Antigen - difficult
⢠AMACR (Alpha Methyl Acyl Coenzyme A Racemase)
⢠TFF3
âhigh expression in prostate cancers but
statistically insignificant predictors by using urine
samples
⢠GOLPH2 (Golgi phosphoprotein 2) â in study
53. Limitations
⢠Performance has not been established in patient
had biopsy less than three months ago
⢠Effect of medications unknown
⢠Other diagnostic procedures as radiation may affect
56. Gleason grading system
⢠Original scheme established in the 1960â70s
⢠Incorporated into the WHO classification of prostate
cancer
⢠New âgrade groupâ system proposed by the 2014
ISUP consensus
⢠Adopted by the who classification of tumours of the
prostate in 2016
57. The classical Gleason system
⢠Five histological growth patterns (grades) based on
architectural patterns
⢠Gleason 1 represents the best differentiated
ďmost favorable prognosis,
⢠Gleason 5 the least differentiated
ďpoor prognosis.
58. ⢠Gleason pattern 1 - well-circumscribed, nodular
lesion- VERY RARE
⢠Gleason pattern 2 â
âvariations in sizes of the neoplastic glands,
âslightly increased stroma between the glands,
and
âslight irregularity at the periphery of the nodule
ârare
59. ⢠Gleason pattern 3 â
âmost common pattern,
âdistinct neoplastic glands,
âtypically small, but often of variable sizes and
âinfiltrating into the stroma in between the benign
glands.
⢠Gleason pattern 4 â
⢠fused glands, no individual or distinct gland,
⢠broad, irregular cribriform patterns
60. ⢠Gleason pattern 5 â
âComedo type necrosis
⢠Gleason score = the sum of the primary and
secondary patterns (grades)
⢠With just one pattern, the primary and secondary
patterns are considered the same
61. ⢠The major changes in the 2016 WHO blue book are
âCribriform glands should be assigned Gleason
pattern 4.
âGlomeruloid glands should be assigned Gleason
pattern 4.
âMucinous carcinoma should be assigned Gleason
pattern 4.
⢠According to the 2004 WHO blue book, rare
cribriform glands diagnosed as pattern 3
62. Grade groups:
⢠By 2014 ISUP consensus conference on Gleason
grading of prostatic carcinoma
⢠These grade groups are as follows:
âGrade group 1: Gleason score â¤6
âGrade group 2: Gleason score 3â +â 4â =â 7
âGrade group 3: Gleason score 4â +â 3â =â 7
âGrade group 4: Gleason score 4â +â 4â =â 8, 3â +â 5â =â 8,
5â +â 3â =â 8
âGrade group 5: Gleason scores 9â10
63.
64. Take home message
⢠Prostate cancer is the 2nd most common diagnosed
malignancy (Incidence); Most prevalent cancer of
men
⢠PSA remains the most used marker to detect
carcinoma
⢠Most important limitation is over diagnosis
⢠D'Amico Criteria Risk categorization is done by
combination of PSA, Gleason score, clinical stage
65. ⢠PSA velocity >2.0 ng /ml -higher risk of metastasis
⢠The risk of having cancer increases if the free to
total PSA ratio is less than 25%
⢠Post-treatment PSA becomes undetectable within a
few weeks
⢠PCA3 is highly overexpressed in prostate cancer
(10â100-fold)
⢠Urine-based PCA3 estimation by RT-qPCR
66. ⢠TMPRSS2:ERG fusion gene estimated from urine by
RT-qPCR
⢠Therapy resistance can determined by CTC
⢠Prostate-Specific Membrane Antigen is a marker of
prognosis
⢠Gleason grading system based on architectural
patterns
⢠WHO Grading 2016 based on modified Gleason
grading, the grade groups